Gaurav Kaushik1, Deep Kwatra2, Dharmalingam Subramaniam3, Roy A Jensen4, Shrikant Anant5, Joshua M V Mammen6. 1. Department of Surgery, The University of Kansas School of Medicine, 3901 Rainbow Boulevard, Kansas City, KS 66160, USA. 2. Department of Molecular and Integrative Physiology, The University of Kansas School of Medicine, 3901 Rainbow Boulevard, Kansas City, KS 66160, USA; Department of Pathology, The University of Kansas School of Medicine, 3901 Rainbow Boulevard, Kansas City, KS 66160, USA. 3. Department of Molecular and Integrative Physiology, The University of Kansas School of Medicine, 3901 Rainbow Boulevard, Kansas City, KS 66160, USA. 4. Department of Pathology, The University of Kansas School of Medicine, 3901 Rainbow Boulevard, Kansas City, KS 66160, USA. 5. Department of Surgery, The University of Kansas School of Medicine, 3901 Rainbow Boulevard, Kansas City, KS 66160, USA; Department of Molecular and Integrative Physiology, The University of Kansas School of Medicine, 3901 Rainbow Boulevard, Kansas City, KS 66160, USA; Department of Pathology, The University of Kansas School of Medicine, 3901 Rainbow Boulevard, Kansas City, KS 66160, USA. 6. Department of Surgery, The University of Kansas School of Medicine, 3901 Rainbow Boulevard, Kansas City, KS 66160, USA; Department of Molecular and Integrative Physiology, The University of Kansas School of Medicine, 3901 Rainbow Boulevard, Kansas City, KS 66160, USA; Department of Pathology, The University of Kansas School of Medicine, 3901 Rainbow Boulevard, Kansas City, KS 66160, USA. Electronic address: jmammen2@kumc.edu.
Abstract
BACKGROUND: Malignant melanoma is an aggressive form of skin cancer with limited effective therapeutic options. Melanoma research concentrates on maximizing the effect on cancer cells with minimal toxicity to normal cells. AMP-activated protein kinase (AMPK) is an important regulator of cellular energy homeostasis and has been shown to control tumor progression regulating the cell cycle, protein synthesis, and cell growth and/or survival. Honokiol (HNK) is a biphenolic compound derived from Magnolia officinalis, a plant that has been used in traditional Chinese and Japanese medicine for the treatment of various pathological conditions. Recent studies have shown that HNK has antitumor activity with relatively low toxicity. In this study, we demonstrated that the growth inhibitory effects of HNK on melanoma and melanoma cancer stem cells were mediated through the activation of AMPK and hence AMPK signaling in melanoma cells. METHODS: We determined the effects of HNK treatment on various melanoma cell lines. HNK-induced cell growth inhibitory effects were determined using hexosaminidase assay. Protein expression studies were done by immunoblotting. Primary spheroid assay was used to assess stemness by growing single suspension cells in ultralow attachment plates. RESULTS: HNK is highly effective in inhibiting melanoma cells by attenuating protein kinase B/mammalian target of rapamycin and AMPK signaling. HNK showed significant inhibition of the spheroid-forming capacity of melanoma cells and, hence, stemness. HNK significantly decreased the number and size of melanospheres in a dose-dependent manner. Western blot analyses showed enhanced phosphorylation of AMPK in melanoma cells. Furthermore, HNK decreased the cellular adenosine triphosphate pool in a dose-dependent manner with maximum effects observed at 48 hours. CONCLUSIONS: The results suggest that HNK can target melanoma cells and mark them for cell death through AMPK signaling. Further studies are warranted for developing HNK as an effective chemopreventive/therapeutic agent in melanoma.
BACKGROUND:Malignant melanoma is an aggressive form of skin cancer with limited effective therapeutic options. Melanoma research concentrates on maximizing the effect on cancer cells with minimal toxicity to normal cells. AMP-activated protein kinase (AMPK) is an important regulator of cellular energy homeostasis and has been shown to control tumor progression regulating the cell cycle, protein synthesis, and cell growth and/or survival. Honokiol (HNK) is a biphenolic compound derived from Magnolia officinalis, a plant that has been used in traditional Chinese and Japanese medicine for the treatment of various pathological conditions. Recent studies have shown that HNK has antitumor activity with relatively low toxicity. In this study, we demonstrated that the growth inhibitory effects of HNK on melanoma and melanoma cancer stem cells were mediated through the activation of AMPK and hence AMPK signaling in melanoma cells. METHODS: We determined the effects of HNK treatment on various melanoma cell lines. HNK-induced cell growth inhibitory effects were determined using hexosaminidase assay. Protein expression studies were done by immunoblotting. Primary spheroid assay was used to assess stemness by growing single suspension cells in ultralow attachment plates. RESULTS: HNK is highly effective in inhibiting melanoma cells by attenuating protein kinase B/mammalian target of rapamycin and AMPK signaling. HNK showed significant inhibition of the spheroid-forming capacity of melanoma cells and, hence, stemness. HNK significantly decreased the number and size of melanospheres in a dose-dependent manner. Western blot analyses showed enhanced phosphorylation of AMPK in melanoma cells. Furthermore, HNK decreased the cellular adenosine triphosphate pool in a dose-dependent manner with maximum effects observed at 48 hours. CONCLUSIONS: The results suggest that HNK can target melanoma cells and mark them for cell death through AMPK signaling. Further studies are warranted for developing HNK as an effective chemopreventive/therapeutic agent in melanoma.
Authors: M Bettencourt-Dias; R Giet; R Sinka; A Mazumdar; W G Lock; F Balloux; P J Zafiropoulos; S Yamaguchi; S Winter; R W Carthew; M Cooper; D Jones; L Frenz; D M Glover Journal: Nature Date: 2004-12-23 Impact factor: 49.962
Authors: Simon A Hawley; David A Pan; Kirsty J Mustard; Louise Ross; Jenny Bain; Arthur M Edelman; Bruno G Frenguelli; D Grahame Hardie Journal: Cell Metab Date: 2005-07 Impact factor: 27.287
Authors: Simon A Hawley; Jérôme Boudeau; Jennifer L Reid; Kirsty J Mustard; Lina Udd; Tomi P Mäkelä; Dario R Alessi; D Grahame Hardie Journal: J Biol Date: 2003-09-24
Authors: Dasha E Kenlan; Piotr Rychahou; Vitaliy M Sviripa; Heidi L Weiss; Chunming Liu; David S Watt; B Mark Evers Journal: Mol Cancer Ther Date: 2017-03-03 Impact factor: 6.261
Authors: Fangfang Bi; Ziyan Jiang; Wonmin Park; Tobias M P Hartwich; Zhiping Ge; Kay Y Chong; Kevin Yang; Madeline J Morrison; Dongin Kim; Jaeyeon Kim; Wen Zhang; Liliia M Kril; David S Watt; Chunming Liu; Yang Yang-Hartwich Journal: Mol Cancer Ther Date: 2021-10-08 Impact factor: 6.009
Authors: Jin Sun Lee; Ji Young Sul; Jun Beom Park; Myung Sun Lee; Eun Young Cha; Young Bok Ko Journal: Int J Mol Med Date: 2019-03-05 Impact factor: 4.101